Skip to main content
Erschienen in: Antimicrobial Resistance & Infection Control 1/2020

Open Access 01.12.2020 | Research

Oral colonisation by antimicrobial-resistant Gram-negative bacteria among long-term care facility residents: prevalence, risk factors, and molecular epidemiology

verfasst von: Mi Nguyen-Tra Le, Shizuo Kayama, Mineka Yoshikawa, Toshinori Hara, Seiya Kashiyama, Junzo Hisatsune, Keiko Tsuruda, Makoto Onodera, Hiroki Ohge, Kazuhiro Tsuga, Motoyuki Sugai

Erschienen in: Antimicrobial Resistance & Infection Control | Ausgabe 1/2020

Abstract

Background

For residents of long-term care facilities (LTCFs), antimicrobial-resistant bacteria (ARB) are a risk factor, yet their oral colonisation, potentially leading to aspiration pneumonia, remains unclear. This study was undertaken to survey the prevalence, phenotypic characteristics, and molecular epidemiology of antimicrobial-resistant Gram-negative bacteria in the oral cavity of LTCF residents, and to analyse the risk factors for such carriers.

Methods

This study involved 98 residents of a LTCF in Hiroshima City, Japan, aged between 55 and 101 years. Oropharyngeal swabs were collected and plated on screening media for ESBL-producing and carbapenem-resistant bacteria; isolates were identified and tested for antibiotic susceptibility; biofilm formation was tested in vitro; identification of epidemic clones were pre-determined by PCR; resistance genes, sequence types, and whole-genome comparison of strains were conducted using draft genome sequences. Demographic data and clinical characterisations were collected and risk factors analysed.

Results

Fifty-four strains from 38% of the residents grew on screening media and comprised predominantly of Acinetobacter spp. (35%), Enterobacteriaceae spp. (22%), and Pseudomonas spp. (19%). All Escherichia coli isolates carried CTX-M-9 group and belonged to the phylogroup B2, O25:H4 ST131 fimH30 lineage. Six Acinetobacter baumannii isolates presented identical molecular characteristics and revealed more biofilm production than the others, strongly suggesting their clonal lineage. One Acinetobacter ursingii isolate displayed extensive resistance to various ß-lactams due to multiple acquired resistance genes. One Pseudomonas aeruginosa isolate showed exceptional resistance to all ß-lactams including carbapenems, aminoglycosides, and a new quinolone, showing a multidrug-resistant Pseudomonas aeruginosa (MDRP) phenotype and remarkable biofilm formation. Genome sequence analysis revealed this isolate was the blaIMP-1-positive clone ST235 in Japan. Strokes (cerebral infarction or cerebral haemorrhage) and percutaneous endoscopic gastrostomy tubes were recognised as risk factors for oral colonisation by ARB in the LTCF residents.

Conclusions

ARB, as defined by growth on screening agar plates, which carried mobile resistance genes or elements or conferred high biofilm formation, were already prevalent in the oral cavity of LTCF residents. Health-care workers involved in oral care should be aware of antimicrobial resistance and pay special attention to transmission prevention and infection control measures to diminish ARB or mobile resistance elements dissemination in LTCFs.
Hinweise

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s13756-020-0705-1.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARB
Antimicrobial-resistant bacteria
BRIG
Blast ring image generator
CI
Confidence interval
CLSI
By clinical laboratory standards institute
ESBL
Extended-spectrum ß-lactamase
LB
Luria-bertani
LTCF
Long-term care facility
MBL
Metallo-ß-lactamase
MDR
Multidrug resistant
MIC
Minimum inhibitory concentration
MLST
Multilocus sequence typing
NHAP
Nursing home-acquired pneumonia
OR
Odds ratios
PBS
Phosphate buffered saline
PEG
Percutaneous endoscopic gastrotomy
POT
PCR-based ORF typing
QRDR
Quinolone resistance-determining region
WGS
Whole genome sequences

Background

Extensive consumption of antibiotics has been the crucial pressure impelling drug-resistance, leading to the global concern of multi-antimicrobial resistant microorganisms. While much attention has been paid to infectious diseases by multidrug-resistant (MDR) organisms in severely ill patients in intensive care units, the colonisation by antimicrobial-resistant bacteria (ARB) among patients in long-term care facilities (LTCFs) has been thus far neglected. Since the early 1970s, various reports have repeatedly emphasised the role of asymptomatic patients in LTCFs as a reservoir of ARB thus favouring their persistent colonisation and extensive dissemination throughout hospital settings [1].
A similar situation is developing across Japan, where the percentage of elderly over 65 years is predicted to be as much as 38.1% [2] by 2060, whilst health care-associated infection management in LTCFs is straggling in comparison with the one in medical settings. Adequate active surveillances still have to clarify the colonisation rates by MDR bacteria among the elderly residing in LTCFs nationwide [3]. Moreover, surveillances for ARB carriage among LTCFs residents have been almost exclusively for faecal or rectal samples [4].
The oral cavity is constantly exposed to external material during its function of air, beverage, and food intake, thus frequently exposed to various microorganisms. Specific histological features of the mouth (e.g., the papillary dorsal tongue, the mucosal epithelia of cheeks, the teeth enamel, and the periodontal surfaces), in addition to changes in the ecological condition (e.g., the salivary flow) may result in the accumulation of host-produced extracellular pellicles and the subsequent formation of a biofilm, a favourable matrix for nutrition supply. Exposure of bacteria to such pellicle-facilitated surfaces over several hours promotes the colonisation by those pathogens in this biotic niche [5]. The persistence of such organisms in the oropharyngeal area, in turn, places the patients at risk for bacterial pneumonia [6].
While previous published data of this target population mainly focused on faecal or rectal samples to evaluate the carriage of ARB [4], a survey by March A. et al. indicated a proportion of ARB present in the oropharyngeal area in addition to the other sites [7]. However, to date, few researchers have addressed this issue in the oral cavity. For those reasons, this paper addresses (i) the prevalence of oral colonisation by ARB, including extended-spectrum ß-lactamases (ESBLs)-producing and carbapenem-resistant bacteria, among the LTCF residents, (ii) risk factors associated with colonisation by AMR organisms, and (iii) molecular epidemiology to figure out if any further necessary preventive measures should be implemented.

Materials and methods

Bacterial strains

Pseudomonas aeruginosa PA160071 and PA058447, strong biofilm-forming strains, and P. aeruginosa PAO1 served as controls. PA160071 is a blaIMP-1-positive ST235 In113-carrying P. aeruginosa (carrier of type E integron [8]), which is similar to NCGM2.S1, an epidemic MDR ST235 P. aeruginosa isolated in North Japan (Tohoku region) [9, 10]. PA058447 is a blaIMP-1-positive type F integron-carrying MDR P. aeruginosa, an epidemic ST235 in the Hiroshima region [11].

Study design and participants

This study was performed to assess the prevalence of oral and pharyngeal carriage of antimicrobial-resistant Gram-negative bacteria in an LTCF, from February 2017 to January 2018. A total of 98 residents in a geriatric facility located in Hiroshima city, Hiroshima Prefecture, were included in the study. Informed consent was obtained from the residents or their relatives. This study has been approved by the ethical committee of the Hiroshima University Hospital review board (E-1704).

Phenotypic characterisation

To screen for the carriage of ARB, oropharyngeal swabs were taken from all patients and spread directly onto CHROMagar™ ESBL and CHROMagar™ mSuperCARBA™ medium plates (Kanto Chemical, Japan). CHROMagar™ ESBL is a screening medium for rapid and presumptive identification of ESBL-producing Enterobacteriaceae [12]. Although the formulation of this medium is proprietary, the CHROMagar™ ESBL supplement allows the detection of ESBL-producing bacteria while inhibiting the growth of other bacteria, including most of those carrying ampC type resistance. CHROMagar™ mSuperCARBA™ is a screening medium for the detection of carbapenemase-producing Enterobacteriaceae [13]. Plates were incubated for 18–24 h at 37 °C and colony growth observed after incubation. All positive colonies were sub-cultured onto secondary plates to confirm the resistance, and those grown on Candida GE plate were eliminated. Bacteria grown on the second screen were considered ARB.
Identification and antimicrobial susceptibility tests were conducted using Vitek-2 System (bioMérieux, France). Species unidentifiable by this system were further investigated using 16S rDNA sequencing and MALDI-TOF MS-Biotyper (Bruker Daltonics, Yokohama, Japan). The antibiotics used for the susceptibility tests included: Ampicillin, Piperacillin, Tazobactam/Piperacillin, Ampicillin/Sulbactam, Cefazolin, Ceftazidime, Cefotaxim, Cefozopran, Cefoperazone/Sulbactam, Cefpodoxime, Imipenem, Meropenem, Doripenem, Amikacin, Ciprofloxacin, Levofloxacin, Minocyclin, Fosfomycin, Sulfamethoxaxole, and Azidothymidine. Results were interpreted according to guideline M100-S25 from the Clinical Laboratory Standards Institute (CLSI) [14].

Biofilm formation assay

To evaluate biofilm formation of the strains, a biofilm assay using polystyrene plates was conducted as described previously [15], with a few modifications. Each isolate was cultured in 5 mL of Luria-Bertani (LB) broth and incubated overnight at 37 °C. The cultures were diluted 100 times in LB and 10 μL aliquots were transferred to 96-well flat bottom polystyrene plates (Nippon Genetics Co., Japan) containing 100 μL LB or LB plus 1% glucose. Thereafter, plates were incubated at 37 °C for 24 h. Further, plates were gently washed three times with 300 μL phosphate buffered saline (PBS) followed by staining with 1% crystal violet for 15 min. Afterwards, the plates were washed by immersion in a water tub and stirred 10 times to eliminate the unbound crystal violet. The stained biofilms were solubilised in 200 μL of 33% glacial acetic acid for 15 min followed with a 10-fold dilution; OD590 nm was determined with the Varioskan® Flash spectral scanning multimode reader (Thermo Fisher Scientific, USA).

Genomic characterisation

To check for the presence of resistance elements among the isolates, PCR amplification was performed to screen the extended spectrum ß-lactamase genes group (blaCTX-M-1, blaCTX-M-2, blaCTX-M-8, blaCTX-M-9, blaTEM and blaSHV) and carbapenemases genes (blaIMP, blaOXA, blaNDM, blaKPC, blaVIM and blaFIM) (Supplementary Table 1) using Quick Taq HS DyeMix (Toyobo, Japan). The cycling protocol was as follows: denaturation at 95 °C for 5 min, 35 cycles of 95 °C for 30 s, 52 °C for 30 s, 68 °C for 90 s, and 72 °C for 5 min.
We further selected the organisms of interest from those having higher prevalence across our study, namely Acincetobacter spp., Pseudomonas spp., and Escherichia coli. For these isolates, the clonal identification and molecular typing was carried out with the PCR-based ORF Typing method (POT method) [16] using specific POT kits: Cica Geneus® Acineto POT KIT, Cica Geneus® E. coli POT KIT, and Cica Geneus® Pseudo POT KIT (Kanto Chemical, Japan) for each strain according to the manufacturer’s instructions. The POT codes were converted from the results of electrophoretic band patterns. The isolate characterisation (epidemic clones, sequence type, resistance genes) and homology between strains were subsequently interpreted.
To further determine the phylogenetic group (A, B1, B2, and D) of E. coli strains, a rapid and simple protocol was performed as described previously [17]. In brief, three pairs of primers were used: ChuA.1 and ChuA.2, YjaA.1 and Yja.2, and TspE4C2.1 and TspE4C2.2 (Supplementary Table 1) to amplify the DNA fragments of 279, 211, and 152 base pairs, respectively. The thermal cycle conditions were as follow: denaturation for 4 min at 94 °C, 30 cycles of 30 s, 94 °C; 30 s, 65 °C; 30 s, 72 °C; followed by 5 min at 72 °C. The clades of E. coli sequence type (ST) 131 were identified according to Matsumura et al. [18].
The isolates, which were high biofilm producers, resistant to multiple antimicrobials by MICs or positive for antimicrobial-resistance (AMR) genes by PCR, were selected for genome sequencing. Whole genome sequences (WGS) of E. coli isolates 43E, 73E, 77E, and 95E, A. baumannii isolates 13C, 41C, 45C, 50E-B, 51E, and 52E, A. ursingii isolate 56C, and P. aeruginosa isolate 71E were obtained using Illumina MiSeq sequencing platform, followed by annotation with the Rapid Annotation using Subsystem Technology (RAST) version 2.0 [19]. The multilocus sequence typing (MLST) and acquired AMR genes were identified with the MLST and ResFinder pipeline [20, 21] available from the Center for Genomic Epidemiology (Lyngby, Denmark) with default settings and whole genome sequence (WGS) raw reads for the analysis. Genome comparison of E. coli isolates 43E, 73E, 77E, and 95E was performed using Blast Ring Image Generator (BRIG) version 0.95 [22] with reference to the complete WGS of E. coli K-12 MG1655 strain (accession number NC_000913), a well-studied and approximated wild-type E. coli, and two ST131 E. coli namely E. coli EC958 (HG941718) and E. coli H105 (CP021454) strains. Similarly, genome comparison of A. baumannii 13C, 41C, 45C, 50E-B, 51E, 52E, and 56C isolates was performed with reference to the complete WGS of A. baumannii ATCC17978 strain (NZ_CP018664), and genome comparison of P. aeruginosa PA71E and PA058447 strains was performed with reference to the available complete WGS of NCGM2.S1 (AP012280) and PAO1 (NC_002516) strains.

Epidemiological investigation and data analysis

To investigate the risk factors for colonisation by ARB, demographic data of the patients were retrieved from their hospital records, including age, sex, LTCF ward, comorbidities (dementia, strokes (cerebral infarction or cerebral haemorrhage), cardiovascular diseases, diabetes, cancers, fractures, arthropathy), oral motor dysfunction (dysarthria or dysphagia), oral care ability, and denture wearing.
Univariate statistical method (X2 test for categorical variables) was performed to compare the baseline demographics and clinical variables between the patients who were colonised with ARB and those who were not. Associations were analysed using chi-square test or Fisher’s exact test. Odds ratios (OR) and 95% confidence interval (CI) were displayed to indicate the relation strength. All analyses were performed using IBM SPSS statistics software, version 22. Statistical significance was designated as a two-sided P value ≤ 0.05.

Results

Epidemiological investigation and risk factors associated with colonisation

Overall, 98 patients from the LTCF were recruited and participated in this study. The mean age was 83.34 ± 9.47 years (55 to 101 years old), 39 were men (30%) with a mean age of 80.76 ± 9.44 years (60 to 96 years old) and 69 women (70%) with 84.42 ± 9.34 years (55 to 101 years old).
From the screening by screening media, 51 ARBs were detected by CHROMagar™ ESBL and 49 ARBs were detected by CHROMagar™ mSuperCARBA™. Altogether, a total of 54 isolates from 37 patients (38%) were detected as ARB using screening agar plates. Those isolates belonged to three main genera: Acinetobacter, Enterobacteriaceae, and Pseudomonas spp. (Fig. 1). The number of isolates for each species is listed in Supplementary Table 2. The most common species comprised A. baumannii (10 isolates, 19%), Stenotrophomonas maltophilia (6 isolates, 11%), Chryseobacterium indologenes (5 isolates, 9%), and E. coli (4 isolates, 7%). Of 98 residents enrolled, 27% were colonised with a single ARB, 7% were colonised with two ARBs, and 4% were colonised with three ARBs. Among these 54 ARBs, 46 isolates from 32 patients (33%) were confirmed as having reduced susceptibility to one or more tested antimicrobial agents, 29 isolates from 23 patients (23%) were confirmed as cephalosporin-resistant ARB, and 13 isolates from 13 patients (13%) were confirmed as carbapenem-resistant ARB by Vitek-2.
Demographics and clinical characteristics of all patients divided in two groups, ARB-positive and ARB-negative, are shown in Table 1. Two risk factors, strokes (cerebral infarction or cerebral haemorrhage) (OR 3.46, 95% CI 1.38–8.70, p = 0.007) and percutaneous endoscopic gastrotomy tubes (PEG tubes) (Fisher’s exact test, p = 0.002), indicated the existence of ARB in the oral cavity. In particular, 43.2% (n = 16) of ARB-positive individuals underwent strokes, outweighing the percentage of ARB-negative individuals (18% (n = 11)). Similarly, 16.2% (n = 6) of the residents who were ARB-positive carried PEG tubes, exceeding the percentage of the group of ARB-negative residents (0.0% (n = 0)). To a lesser extent, the percentage of patients with dysarthria or dysphagia, diabetes, denture wearing, and male sex tended to be much higher in the ARB-positive group than in the ARB-negative group though no statistically significant differences were found.
Table 1
Clinical characteristics of patients and risk factors associated with oral colonisation by resistant bacteria
Variable
Subjects with ARB-positive, n = 37
Subjects with ARB-negative, n = 61
Univariate analysis
P-value
n (%)
OR
95% CI
 
Age ≥ 90 years, n (%)
12 (32.4)
13 (21.3)
1.77
0.71–4.45
0.22
Male sex, n (%)
14 (37.8)
15 (24.6)
1.87
0.77–4.52
0.16
Ward, n (%)
    
0.92
 1st floor
10 (27.0)
17 (27.9)
0.96
0.38–2.40
0.93
 2nd floor
14 (37.8)
25 (41.0)
0.88
0.38–2.03
0.76
 3rd floor
13 (35.1)
19 (31.1)
1.20
0.50–2.85
0.68
Dementia
15 (40.5)
31 (50.8)
0.66
0.29–1.51
0.32
Strokes (cerebral infarction/ cerebral haemorrhage)
16 (43.2)
11 (18.0)
3.46
1.38–8.70
0.007**
Cardiovascular diseases
15 (40.5)
19 (31.1)
1.51
0.64–3.53
0.34
Diabetes
10 (27.0)
10 (16.4)
1.89
0.70–5.10
0.21
Cancers
1 (2.7)
5 (8.2)
  
0.40a
Fractures
5 (13.5)
11 (18.0)
0.71
0.23–2.24
0.56
Arthropathy
2 (5.4)
2 (3.3)
  
0.63a
Dysarthria or dysphagia
13 (35.1)
12 (19.7)
2.21
0.88–5.57
0.09
Inappropriate oral care
18 (48.6)
26 (42.6)
1.28
0.56–2.90
0.56
Denture wearing
24 (64.9)
32 (52.5)
1.67
0.72–3.88
0.23
Percutaneous endoscopic gastrotomy tubes (PEG tubes)
6 (16.2)
0 (0.0)
  
0.002a,**
OR Odds ratio, CI Confidence interval
a Fisher’s Exact Test
*P value ≤ 0.05, **P value ≤ 0.01

Phenotypic and genomic characterisation

The presence of PCR-based POT code and antibiotic susceptibility of individual strains through Vitek-2 are presented in Tables 2. All four E. coli isolates were resistant to many ß-lactams and ciprofloxacin. Phylogenetic analysis indicated their phylogroups as B2 lineage: positive for all chuA genes, yjaA genes, and the TSPE4C2 DNA fragment. The POT method identified all those isolates belonging to ST131 carrying blaCTX-M-9 group gene. ST131 clade PCR assay and C1-M27 subclade PCR assay [18] revealed all those isolates pertained to the C1-M27 subclade. Furthermore, this implied the O serotypes and fimH types of O25b-fimH30 and the presence of blaCTX-M-27, a subgroup of CTX-M-9 group. WGS of these isolates confirmed their ST131, serotype O25:H4, fimH30, and carried multiple plasmid-mediated AMR genes (Table 3). In terms of ß-lactam resistance genes, E. coli isolates 43E, 73E, and 77E were found to carry blaCTX-M-27, while E. coli isolate 95E carried blaCTX-M-14 (belonged to CTX-M-9 group) and blaTEM-1B. Besides, their DNA sequences of the chromosomal QRDRs (quinolone resistance-determining regions) of gyrA and parC showed 100% identity with those of MDR ST131 E. coli EC958 and H105 strains, which conferred point mutations involving amino acid substitutions. Substitutions were identified at two codons of GyrA: 83 (Ser → Leu) and 87 (Asp → Asn), and two codons of ParC: 80 (Ser → Ile) and 84 (Glu → Val). Genome comparison of these E. coli isolates with two MDR ST131 E. coli strains (EC958 and H105) through BRIG using the complete WGS of E. coli K-12 MG1655 as a reference, revealed high homology among our four isolates and EC958 and H105 strains with identical missing fragments in comparison with K-12 MG1655 (Fig. 3a), suggesting their close origin.
Table 2
Genotypic characterisations by PCR and antimicrobial susceptibility of all ARB isolates
Isolate’s code
Species
Patients’ ward (floor)
POT code
MIC (μg/mL)
ABPC
PIPC
T/P
A/S
CEZ
CAZ
CTX
CZOP
CPDX
IMP
MEPM
AMK
CPFX
FOM
ST
61E
Acinetobacter baumannii
3
8–13-0
4 (S)
≤8 (S)
≤2 (S)
1 (S)
4 (S)
≤0.5 (S)
1 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
66C
Acinetobacter baumannii
3
8–13-0
16 (S)
≤8 (S)
≤2 (S)
2 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
25E
Acinetobacter baumannii
2
32–20-41
16 (S)
≤8 (S)
> 16 (R)
4 (S)
16 (I)
> 16 (R)
> 8 (R)
4 (I)
2 (S)
2 (I)
<=32 (S)
≤20 (S)
13C
Acinetobacter baumannii
3
104–12-10
8 (S)
≤8 (S)
≤2 (S)
4 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
0.25 (S)
> 128 (R)
≤20 (S)
41C
Acinetobacter baumannii
2
104–12-10
32 (I)
16 (S)
4 (S)
8 (S)
8 (S)
1 (S)
≤0.25 (S)
0.5 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
45C
Acinetobacter baumannii
2
104–12-10
32 (I)
32 (I)
4 (S)
8 (S)
16 (I)
2 (S)
≤0.25 (S)
1 (S)
≤1 (S)
≤0.25 (S)
128 (I)
≤20 (S)
50E-B
Acinetobacter baumannii
2
104–12-10
8 (S)
≤8 (S)
≤2 (S)
2 (S)
4 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
128 (I)
≤20 (S)
51E
Acinetobacter baumannii
2
104–12-10
4 (S)
≤8 (S)
≤2 (S)
2 (S)
4 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
128 (I)
≤20 (S)
52E
Acinetobacter baumannii
2
104–12-10
8 (S)
≤8 (S)
≤2 (S)
4 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
128 (I)
≤20 (S)
12C-C
Acinetobacter baumannii
3
104–13-8
8 (S)
≤8 (S)
≤2 (S)
2 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
2 (S)
≤0.25 (S)
128 (I)
≤20 (S)
70C
Acinetobacter nosocomialis
2
2090-44-10
> 64 (R)
> 64 (R)
16 (I)
> 16 (R)
> 32 (R)
> 16 (R)
≤0.25 (S)
1 (S)
≤1 (S)
0.5 (S)
128 (I)
≤20 (S)
67C-B
Acinetobacter sp. close to 13TU
3
3045-12-10
64 (I)
32 (I)
≤2 (S)
> 16 (R)
> 32 (R)
2 (S)
≤0.25 (S)
0.5 (S)
2 (S)
1 (S)
128 (I)
≤20 (S)
59C-B
Acinetobacter sp. close to 13TU
3
3109-12-10
64 (I)
16 (S)
≤2 (S)
4 (S)
8 (S)
4 (S)
≤0.25 (S)
0.5 (S)
2 (S)
≤0.25 (S)
128 (I)
≤20 (S)
56C
Acinetobacter ursingii
2
4000-50-16
> 64 (R)
> 16 (R)
> 16 (R)
> 16 (R)
> 32 (R)
> 16 (R)
≤0.25 (S)
0.5 (S)
≤1 (S)
1 (S)
64 (S)
> 40 (R)
68E
Acinetobacter baylyi
2
 
4 (S)
8 (S)
≤2 (S)
4 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
25C
Acinetobacter sp.
2
4000-2-16
> 64 (R)
16 (S)
4 (S)
8 (S)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
32E
Acinetobacter sp.
2
4000-2-16
16 (S)
≤8 (S)
≤2 (S)
16 (I)
8 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
128 (I)
≤20 (S)
65C
Acinetobacter sp.
3
4000-2-16
16 (S)
≤8 (S)
≤2 (S)
> 16 (R)
16 (I)
1 (S)
≤0.25 (S)
0.5 (S)
2 (S)
0.5 (S)
128 (I)
≤20 (S)
71C
Acinetobacter sp.
1
4064-4-1
8 (S)
≤8 (S)
≤2 (S)
8 (S)
8 (S)
1 (S)
≤0.25 (S)
≤0.25 (S)
2 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
73E
Escherichia coli
1
49–56-83
> 16 (R)
> 64 (R)
≤8 (S)
16 (I)
> 16 (R)
> 16 (R)
> 32 (R)
> 16 (R)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
2 (S)
> 2 (R)
≤20 (S)
43E
Escherichia coli
2
49–58-19
> 16 (R)
> 64 (R)
≤8 (S)
4 (S)
> 16 (R)
8 (R)
16 (R)
16 (R)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
4 (S)
> 2 (R)
≤20 (S)
95E
Escherichia coli
1
49–62-235
> 16 (R)
> 64 (R)
≤8 (S)
> 16 (R)
> 16 (R)
4 (S)
> 32 (R)
> 16 (R)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
32 (I)
> 2 (R)
> 40 (R)
77E
Escherichia coli
1
49–122-83
> 16 (R)
> 64 (R)
≤8 (S)
8 (S)
> 16 (R)
4 (S)
32 (R)
> 16 (R)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
4 (S)
> 2 (R)
≤20 (S)
7C
Klebsiella pneumoniae
3
> 16 (R)
16 (S)
≤8 (S)
4 (S)
1 (S)
≤0.5 (S)
≤1 (S)
≤0.5 (S)
≤2 (S)
0.5 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
87C
Klebsiella pneumoniae
2
> 16 (R)
4 (S)
≤8 (S)
4 (S)
1 (S)
≤0.5 (S)
≤1 (S)
≤0.5 (S)
≤2 (S)
≤0.25 (S)
≤0.25 (S)
2 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
12C-A
Klebsiella aerogenes
3
> 16 (R)
32 (I)
32 (I)
> 16 (R)
> 16 (R)
> 16 (R)
> 32 (R)
≤0.5 (S)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
64 (S)
≤20 (S)
91C
Raoultella planticola
1
4 (S)
≤8 (S)
≤0.5 (S)
≤1 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
64 (S)
≤20 (S)
82E
Enterobacter cloacae
1
> 16 (R)
16 (S)
16 (S)
> 16 (R)
> 16 (R)
16 (R)
32 (R)
≤0.5 (S)
> 4 (R)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
102C-B
Serratia marcescens
2
16 (I)
≤2 (S)
≤8 (S)
8 (S)
> 16 (R)
≤0.5 (S)
≤1 (S)
≤0.5 (S)
≤2 (S)
0.5 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
18C-A
Morganella morganii
3
> 16 (R)
4 (S)
≤8 (S)
> 16 (R)
> 16 (R)
2 (S)
≤1 (S)
≤0.5 (S)
> 4 (R)
4 (S)
≤0.25 (S)
8 (S)
≤0.25 (S)
> 128 (R)
≤20 (S)
101E
Rahnella sp.
1
4 (S)
≤8 (S)
≤0.5 (S)
≤1 (S)
≤0.5 (S)
0.5 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
71E
Pseudononas aeruginosa
1
207–1
> 64 (I)
> 64 (I)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
> 2 (R)
> 128 (R)
> 40
18C-B
Pseudononas aeruginosa
3
108–2
 
4 (S)
4 (S)
  
2 (S)
 
≤0.5 (S)
 
0.5 (S)
0.5 (S)
4 (S)
≤0.25 (S)
 
> 40
96C
Pseudononas aeruginosa
1
641–0
 
≤2 (S)
≤2 (S)
  
1 (S)
 
2 (S)
 
1 (S)
≤0.25 (S)
4 (S)
0.5 (S)
 
40
89C
Pseudononas aeruginosa
1
696–16
 
4 (S)
4 (S)
  
1 (S)
 
≤0.5 (S)
 
1 (S)
0.5 (S)
2 (S)
≤0.25 (S)
 
> 40
59C-A
Pseudononas fluorescens/putida
3
8 (S)
≤8 (S)
2 (S)
16 (I)
1 (S)
1 (S)
2 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
67C-A
Pseudononas fluorescens/putida
3
8 (S)
≤8 (S)
1 (S)
16 (I)
≤0.5 (S)
1 (S)
1 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
82C
Pseudononas fluorescens/putida
1
16 (S)
16 (S)
2 (S)
32 (I)
≤0.5 (S)
0.5 (S)
4 (I)
≤1 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
66E
Pseudomonas sp.
3
16 (S)
16 (S)
4 (S)
16 (I)
≤0.5 (S)
2 (S)
2 (S)
2 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
67E-A
Pseudomonas sp.
3
4 (S)
≤8 (S)
1 (S)
16 (I)
≤0.5 (S)
1 (S)
2 (S)
≤1 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
102E
Pseudononas sp.
2
8 (S)
8 (S)
8 (S)
1 (S)
1 (S)
1 (S)
≤1 (S)
≤0.25 (S)
> 40 (R)
12E-A
Stenotrophomonas maltophilia
3
> 64 (R)
16 (S)
16 (I)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
2 (I)
64 (S)
40 (S)
18E
Stenotrophomonas maltophilia
3
> 64 (R)
> 64 (R)
2 (S)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
1 (S)
≤32 (S)
≤20 (S)
20C
Stenotrophomonas maltophilia
3
> 64 (R)
> 64 (R)
4 (S)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
2 (I)
> 128 (R)
≤20 (S)
26E
Stenotrophomonas maltophilia
2
> 64 (R)
32 (I)
2 (S)
32 (I)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
1 (S)
128 (I)
≤20 (S)
62C
Stenotrophomonas maltophilia
3
> 64 (R)
> 64 (R)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
2 (I)
128 (I)
40 (S)
101C
Stenotrophomonas maltophilia
1
> 64 (R)
> 64 (R)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
2 (I)
64 (S)
≤20 (S)
59E-C
Chryseobacterium indologenes
3
64 (I)
64 (I)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
1 (S)
> 128 (R)
40 (I)
60E
Chryseobacterium indologenes
3
> 64 (R)
64 (I)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
1 (S)
> 128 (R)
> 40 (R)
65E-B
Chryseobacterium indologenes
3
64 (I)
16 (S)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
> 32 (R)
0.5 (S)
> 128 (R)
> 40 (R)
78E
Chryseobacterium indologenes
1
64 (I)
32 (I)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
32 (I)
1 (S)
> 128 (R)
≤20 (S)
102C-A
Chryseobacterium indologenes
2
> 64 (R)
64 (I)
> 16 (R)
> 32 (R)
> 16 (R)
> 8 (R)
> 8 (R)
32 (I)
0.5 (S)
> 128 (R)
≤20 (S)
64E
Aeromonas salmonicida
3
≤2 (S)
≤8 (S)
≤0.5 (S)
2 (S)
≤0.5 (S)
≤0.25 (S)
≤0.25 (S)
≤1 (S)
≤0.25 (S)
≤32 (S)
≤20 (S)
78C
Ochrobactrum sp.
1
> 64 (R)
> 64 (R)
> 16 (R)
16 (I)
2 (S)
1 (S)
1 (S)
8 (S)
≤0.25 (S)
> 128 (R)
> 40 (R)
POT PCR-based ORF typing, ABPC Ampicillin, PIPC Piperacillin, T/P Tazobactam/piperacillin, A/S, Ampicillin/sulbactam, CEZ Cefazolin, CAZ Ceftazidime, CTX Cefotaxim, CZOP Cefozopran, CPDX Cefpodoxime, IMP Imipenem, MEPM, Meropenem, AMK Amikacin, CPFX Ciprofloxacin, FOM Fosfomycin, ST Sulfamethoxazole, S Susceptible, I Intermediate, R Resistant
Table 3
MLST, serotype, Fim type, and AMR genes of the isolates analysed by whole genome sequences
 
E. coli 43E
E. coli 73E
E. coli 77E
E. coli 95E
A. baumannii 13C, 41C, 45C, 50E-B, 51E, 52E
A. ursingii 56C
P. aeruginosa 71E
MLST
ST131
ST131
ST131
ST131
ST130
 
ST235
Serotype
O25:H4
O25:H4
O25:H4
O25:H4
   
FimH type
fimH30
fimH30
fimH30
fimH30
   
Beta-lactam
blaCTX-M-27 (100%)
blaCTX-M-27 (100%)
blaCTX-M-27 (100%)
blaCTX-M-14 (100%)
blaTEM-1B (100%)
blaADC-166 (97.74%)
blaOXA-430 (99.88%)
blaCARB-2 (100%)
blaPDC-35 (100%)
blaOXA-50 (99.87%)
blaIMP-1 (100%)
blaTEM-1B (100%)
Aminoglycoside
aph(3″)-Ib (100%)
aph(6)-Id (100%)
aadA5 (100%)
aph(3″)-Ib (100%)
aph(6)-Id (100%)
aph(3″)-Ib (100%)
aph(6)-Id (100%)
aph(3″)-Ib (100%)
aadA5 (100%)
aac(3)-IId (99.88%)
aac(6′)-Ib3 (99.82%)
 
aac(6′)-Ib3 (99.82%)
aph(3″)-Ib (99.88%)
aph(3′)-Ia (100%)
aph(6)-Id (100%)
aac(6′)-Iae (100%)
aph(3′)-II (100%)
aadA1 (100%)
Fluoroquinolone
   
aac(6′)-Ib-cr (99.49%)
 
aac(6′)-Ib-cr (99.42%)
 
Fosfomycin
      
fosA (100%)
MLS (Macrolide, Lincosamide, Streptogramin B)
mdf(A) (97.81%)
mph(A) (100%)
mdf(A) (97.81%)
mdf(A) (97.81%)
mph(A) (100%)
mph(A) (100%)
mdf(A) (97.81%)
 
mrs(E) (100%)
mph(E) (100%)
 
Phenicol
   
cmlA1 (99.92%)
 
floR (98.35%)
catB7 (100%)
Rifampicin
     
ARR-3 (100%)
 
Sulfonamide
sul2 (100%)
sul1 (100%)
sul2 (100%)
sul2 (100%)
sul1 (100%)
sul2 (100%)
sul1 (100%)
 
sul2 (100%)
sul1 (100%)
sul1 (100%)
Tetracycline
tet(A) (100%)
tet(A) (100%)
tet(A) (100%)
  
tet(39) (99.91%)
 
Trimethoprim
   
dfrA17 (100%)
 
dfrA19 (100%)
 
Resistance of A. baumannii isolates to antibiotics varied among individual strains. To our surprise, the biofilm formation assay demonstrated that the six A. baumannii isolates (No 13C, 41C, 45C, 50E-B, 51E, and 52E) showed higher biofilm formation than the others (Fig. 2a). Remarkably, six isolates demonstrated the same POT code of 104–12-10, suggesting their similar origin. Interestingly, among six patients colonised with the same POT code, five patients were at the 2nd floor and one was at the 3rd floor (Table 2). Two patients carrying the isolates POT code 8–13-0 were at the same floor (3rd floor). MLST analysis using WGS data revealed the six A. baumannii belonged to ST130 (Table 3). Also, the genome comparison of these strains through BRIG using A. baumannii ATCC17978 strain as a reference exhibited high similarity among all the strains, with identical missing fragments in comparison with the ATCC17978 strain (Fig. 3b). Interestingly, among the nine isolates of the other Acinetobacter spp., we found one (No 56C) displayed extensive resistance to multiple drugs (Table 2). Analysis of 16S rRNA and rpoB gene sequences identified this isolate as A. ursingii [23]. In addition, this strain was confirmed to carry extensive AMR genes against various groups of antimicrobials, which were not found in the other six A. baumannii isolates (Table 3).
Among the four P. aeruginosa isolates, No 71E exhibited the exclusive resistance to all tested ß-lactams, and to amikacin, ciprofloxacin, and fosfomycin as well. The blaIMP-1 gene was detected from isolate No 71E through PCR. Strikingly, the P. aeruginosa isolate No 71E exhibited outstanding biofilm formation which far surpassed any other Pseudomonas isolates and was equal to the ability of PA160071 and PA058447 strains in the presence of 1% glucose (Fig. 2b). Even when glucose was absent, isolate 71E revealed a stronger biofilm formation compared to PA160071 and PA058447 strains. WGS of isolate 71E indicated that this isolate belonged to the ST235 and carried type I integron with multiple resistance genes, ß-lactamases blaIMP-1, aminoglycoside-resistance genes aac(6′)-Iae and aadA1, and sulfamethoxazole-resistance gene sul1 (Table 3). BLASTn comparison of WGS of isolate 71E, PA058447, NCGM2.S1, and PAO1strains using NCGM2.S1 as a reference, showed that isolate 71E showed similar characters to both NCGM2.S1 and PA058447 but distinct from PAO1 strain (Fig. 3c).
C. indologenes isolates showed broad resistance to all ß-lactams, including carbapenems but this resistance has been designated as intrinsic resistance by blaIND group, the class B carbapenem-hydrolyzing ß-lactamase genes [24]. Similarly, S. maltophilia displayed extensive resistance to carbapenems and the other ß-lactams due to two intrinsic ß-lactamase genes, blaL1 (class B metallo-ß-lactamase (MBL)) and blaL2 (class A, functional group 2e, clavulanic acid susceptible cephalosporinase) [24]. Two Klebsiella pneumoniae isolates were resistant to ampicillin, which may be caused by their chromosomally-encoded blaSHV-related genes [25], but susceptible to the other ß-lactams. Other sporadic resistant isolates were also identified, such as Klebsiella aerogenes, Enterobacter cloacae, Morganella morganii, Serratia marcescens, and Ochrobactrum sp., some of which displayed extensive resistance to ampicillins and cephalosporins due to their intrinsic resistance, for example, AmpC ß-lactamase CMY-108 in K. aerogenes [26], E. cloacae ß–lactamase A (IP, 8.8) and B (IP, 7.8) in E. cloacae [27], cephalosporinases encoded by ampC-ampR genes in M. morganii [28], and AmpC ß-lactamases in S. marcescens and Ochrobactrum sp. [24]. All of these isolates showed low biofilm formation ability.

Discussion

ARB, as defined by growth on screening agar plates, most commonly Acinetobacter, Enterobacteriaceae, and Pseudomonas spp., were detected in 37 of 98 (38%) LTCF residents. Moreover, some residents were colonised with more than one type of ARB. The presence of ARB in the oral niche poses a potential risk for pulmonary infections, in which certain kinds of Gram-negative bacteria such as P. aeruginosa, E. coli, K. pneumonia and the others have been reported [6]. Our findings reinforced the significant role of LTCF residents as reservoirs for ARB and also brings the attention to the colonisation by ARB in the oral environment besides the other well-documented body areas.
E. coli ST131 has been reported to be responsible for serious extraintestinal infections and medical implications [29]. Meanwhile, the rapid emergence and international dissemination of this clonal group has posed a critical threat to public health due to its significant AMR [30]. In our study, we also determined that all ESBL-producing E. coli isolates belonged to the most-virulent phylogroup B2, were blaCTX-M-27-producing O25:H4 ST131 fimH30 E. coli, and carried mutations in DNA sequences of the chromosomal QRDRs resulting in fluoroquinolone resistance. The mutations in the gyrA QRDR have been found to be the most frequent mutations among fluoroquinolone-resistant E.coli isolates [31]. The high virulence and resistance of fimH30 lineage to fluoroquinolones, one of the most widely used antimicrobials for urinary tract infections, has made this lineage the most epidemiologically successful subclone of E. coli ST131 [32]. Considering the severe complications, MDR, and rapid propagation of this endemic clone, infection control and transmission prevention should be earnestly considered, especially within the vulnerable population in long-term care settings.
Acinetobacter has been recently responsible for multihospital outbreaks in temperate countries increasing the risk for residents in LTCFs, especially those receiving mechanical ventilation [33]. In our study there was no MDR Acinetobacter but seven out of 10 showed susceptibility to antimicrobials according to the MIC determination, six of which showed extensive biofilm production and showed a highly resistant phenotype on screening media. Besides the detection of ARB carrying multiple AMR genes, the presence of isolates with low MIC based on biochemical tests and no acquired AMR genes while still growing on CHROMagar™ ESBL or CHROMagar™ mSuperCARBA plates, and high biofilm-formation ability, was also a noteworthy finding. This inconsistence, in fact, reflects the difference in the AMR phenotype between a planktonic lifestyle of bacteria in MIC biochemical tests and biofilm lifestyle on agar plates, where bacteria are encased in an extracellular matrix that provides them tolerance and resistance mechanisms to combat antimicrobial challenges. For instance, the biofilm matrix provides a barrier for the penetration of antibiotics and hence, decreases bacteria susceptibility. Exopolysaccharides and extracellular DNA play a role in the resistance to antimicrobial agents, or secreted ß-lactamases in the matrix can degrade antimicrobials [34]. The growth of bacteria in the presence of an antimicrobial agent, despite their low MICs by Vitek-2 or the lack of AMR genes, may suggest their growability inside the human body with the presence of that antimicrobial agent. In other words, the low MIC of Vitek-2 does not necessarily mean the bacteria cannot grow in the presence of antimicrobials inside the human body, considering their biofilm lifestyle. From the viewpoint of hospital infection control, the mobile AMR genes or plasmids are significant concerns given their horizontal gene transfer from organism to organism within the health-care setting. However, from the viewpoint of clinical implications, both the AMR gene-carriers and biofilm-producers are important for their resistance phenotype inside the human body, either through the enzyme-mediated mechanism or the biofilm-based mechanism or through a combination of both. Moreover, our six isolates appeared to be clonally disseminated among the hospital ward. Peleg et al. emphasised that the attachment and biofilm formation ability of A. baumannii inside the body and on object surfaces took part in their virulence mechanisms and long endurance within health care settings, thus increased the potential for an epidemic outbreak [35]. Our results also support this hypothesis and lead to the conclusion that strong biofilm-producing A. baumannii should be regarded as a potential risk even though it lacks AMR genes.
A. ursingii 56C showed expanded resistance to various ß-lactams. A. ursingii is an uncommon opportunistic pathogen first described as a novel species in 2001 [36]. Sporadic cases involving serious bloodstream infections, in patients that are either immunocompromised or immunocompetent, have been reported [37, 38]. Although most of these isolates were susceptible to antimicrobial agents, the first report of a carbapenem-resistant A. ursingii from clinical isolates was described in Japan in 2010 [39] followed by a report of three carbapenemase-producing A. ursingii isolates in The Netherlands from September 2015 to June 2016 [40]. In our study, the A. ursingii isolate did not carry any carbapenemase gene such as blaIMP-4 and blaOXA58 but had some AMR genes as the ones carried by the isolates from The Netherland, for example, blaCARB-2, aac(6′)Ib-cr, mph(E), msr(E), sul1, and tet(39).
Another leading emerging nosocomial pathogen that challenges the therapeutic treatment in clinical settings is P. aeruginosa, which confers both AMR phenotype and robust biofilm production, the so-called resistant biofilm-phenotype. Alternatively, Leibovitz et al. designated the biofilm covering the nasogastric-feeding tubes as reservoirs for biofilm-associated persistent P. aeruginosa in the oropharynges [41]. MBL genes coexist with other AMR elements and are commonly carried on mobile gene cassettes in class 1 or 3 integrons inserted into plasmids or in the chromosome [42], thus MBL-producing P. aeruginosa generally has a MDR phenotype. A 2005 outbreak of MDR P. aeruginosa carrying a novel chromosomally encoded class 1 integron, namely In113, later designated as type E integron by our group [8], has been reported in a neurosurgery ward in the Miyagi prefecture [9]. Complete genome sequence of a representative of this endemic cluster, NCGM2.S1 (previously named IMCJ2.S1) revealed that this strain harboured a blaIMP-1 gene cassette and a aac(6′)-Iae gene cassette in the integron In113, promoting the high level of MDR to ß-lactams and aminoglycosides, respectively, without the presence of any plasmids [10]. In the meantime, an epidemic clonal (designated as type F by our group) MDR P. aeruginosa in the Hiroshima region, represented by PA058447, was also noticed from a 9-year longitudinal molecular epidemiology study. This strain was proposed to have identical resistance element sequences as In113-carrying P. aeruginosa (type E) yet a disrupted Intl1 by an IS26 insertion and subsequent genomic reorganisation [11]. Interestingly, those two endemic clones were identified as having the same sequence type, ST235. Our detection of ST235 P. aeruginosa 71E with outstanding biofilm-formation ability, MDR phenotype, and close clonal origin with the epidemic ST235 MDR P. aeruginosa in Hiroshima region has called a conscientious attention.
Although S. maltophilia was not deeply investigated due to its natural resistance, the high prevalence of this species in this LTCF was also noteworthy since this pathogen has been recognised to produce nosocomial pneumonia in patients that are critically ill [43]. Inadequate empirical antimicrobial therapy over such high intrinsic resistance species may fail to defeat the infection, thus caution should be taken when administering medication empirically to those individuals.
Strokes, predominantly cerebral infarction and cerebral haemorrhage, were found to be a significant risk factor for oropharyngeal colonisation by ARB in LTCF. Gill et al. previously stated that stroke was significantly associated with disability in the elderly [44], requiring substantial assistance from care-givers with regards to dressing, toileting, eating, and other daily activities. In addition, faecal incontinence associated with diaper use and nursing aids have been recognised as risk factors for faecal carriage of ESBL-Enterobacteriaceae [45] and were likely linked to ARB transmission mediated via healthcare workers. This explanation is plausible as 14.5% of LTCF staff were colonised with ESBL-producers in the study of March et al. [7]. Besides, contaminated environments and mechanical equipment (e.g., nasogastric tubes, tracheostomy tubes, and urinary catheters) may accelerate the colonisation by nosocomial pathogens specifically those showing vigorous biofilm production. An outbreak of AMR A. baumannii due to the utilisation of contaminated tap water from hygiene sinks for oral care in an intensive care unit was reported [46]. The greater the advanced disability patients have, the more assistance and interaction with care-workers and medical-device operators are required, consequently facilitating the propagation of such microorganisms. In addition, patients who were fed with PEG tubes might undergo a reduction in mastication activity and salivary secretion, hence promoting the pathogenic colonisation inside the oral cavity. Since colonisation is an essential prerequisite for infection [45], the colonisation by ARB in LTCF raises a crucial challenge regarding the shortage of available efficient anti-infective agents once infection occurs.
Recently, to reduce the risk of “nursing home-acquired pneumonia” (NHAP), more effort have been taken to improve oral care such as implementing professional mouth care (brushing teeth, swabbing the mucosa, cleaning dentures, using mouthwash, having dental check-ups by professional dentists, or a combination of those methods) [47], being aware of dysphagia signs [48], improving the staff practices for oral care [49], or promoting oral hygiene, and swallowing ability of the LTCF residents [50]. Professional oral health care was proved to be cost-effective in declining the mortality and morbidity rates from NHAP in German healthcare settings [51]. In a systematic review by the Cochrane Library, despite the lack of high-quality evidence to determine the most effective measures to prevent NHAP, these studies proposed the efficacy in lowering pneumonia mortality through professional oral care when compared to usual oral care after a 24 month-follow up [47]. Whether the professional oral care will be an effective measure to reduce prevalence of ARB remains to be examined.
The study has several potential limitations that deserved to be discussed. First, as a limited number of patients participated in this surveillance, alternative possible risk factors might have not been identified. Second, no historical records of antibiotic use among the residents one year prior to this study were available, hindering the determination of the association between antimicrobial therapy and development of ARB. Third, this surveillance was conducted in a single LTCF, thus the overall prevalence of oral colonisation by ARB among other LTCFs in Japan remains to be elucidated. A similar study should be conducted in a large-scale long-term care system in order to comprehend the general situation and comparative evaluation.

Conclusions

In summary, the present study detected high prevalence of AMR Gram-negative bacteria, ESBL-producing and carbapenem-resistant pathogens relevant to aspiration pneumonia, which carried the resistance genes on mobile elements such as plasmids or integrons or in the chromosome and/or are strong biofilm producers, in the oral cavity of LTCF residents. Health care workers involved in oral care should be aware of such ARB and pay special attention to transmission prevention and infection control to diminish the dissemination of ARB or the mobile resistance elements in LTCFs. Last but not least, with the rapid ageing of the Japanese society, surveillance initiatives and regional and national projects for infection control should not put aside the significant role of LTCFs or nursing homes in the healthcare network.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s13756-020-0705-1.

Acknowledgements

Authors acknowledge the contribution of the hospital who participated in this study. We would like to thank Editage (www.​editage.​com) for English language editing. This work was supported by Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) under grant number JP19fk0108061.
This study has been approved by the ethical committee of Hiroshima University Hospital review board (E-1704).
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Bureau S. Ministry of Internal Affairs and Communications. Japan: Statistical Handbook of Japan; 2018. Bureau S. Ministry of Internal Affairs and Communications. Japan: Statistical Handbook of Japan; 2018.
3.
Zurück zum Zitat Kariya N, Sakon N, Komano J, Tomono K, Iso H. Current prevention and control of health care-associated infections in long-term care facilities for the elderly in Japan. J Infect Chemother. 2018;24(5):347–52.PubMedCrossRef Kariya N, Sakon N, Komano J, Tomono K, Iso H. Current prevention and control of health care-associated infections in long-term care facilities for the elderly in Japan. J Infect Chemother. 2018;24(5):347–52.PubMedCrossRef
4.
Zurück zum Zitat Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E. Extended-spectrum beta-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50(5):649–56.PubMedCrossRef Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E. Extended-spectrum beta-lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50(5):649–56.PubMedCrossRef
6.
Zurück zum Zitat Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med. 1969;281(21):1137–40.PubMedCrossRef Johanson WG, Pierce AK, Sanford JP. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med. 1969;281(21):1137–40.PubMedCrossRef
7.
Zurück zum Zitat March A, Aschbacher R, Dhanji H, Livermore DM, Bottcher A, Sleghel F, et al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect. 2010;16(7):934–44.PubMedCrossRef March A, Aschbacher R, Dhanji H, Livermore DM, Bottcher A, Sleghel F, et al. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin Microbiol Infect. 2010;16(7):934–44.PubMedCrossRef
8.
Zurück zum Zitat Kouda S, Ohara M, Onodera M, Fujiue Y, Sasaki M, Kohara T, et al. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the bla IMP-1 gene cassette in Hiroshima. J Antimicrob Chemother. 2009;64(1):46–51.PubMedCrossRef Kouda S, Ohara M, Onodera M, Fujiue Y, Sasaki M, Kohara T, et al. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the bla IMP-1 gene cassette in Hiroshima. J Antimicrob Chemother. 2009;64(1):46–51.PubMedCrossRef
9.
Zurück zum Zitat Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Fujino T, Kobayashi I, Morita K, et al. Multidrug-resistant Pseudomonas aeruginosa strain that caused an outbreak in a neurosurgery ward and its aac(6′)-Iae gene cassette encoding a novel aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2005;49(9):3734–42.PubMedPubMedCentralCrossRef Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Fujino T, Kobayashi I, Morita K, et al. Multidrug-resistant Pseudomonas aeruginosa strain that caused an outbreak in a neurosurgery ward and its aac(6′)-Iae gene cassette encoding a novel aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2005;49(9):3734–42.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Miyoshi-Akiyama T, Kuwahara T, Tada T, Kitao T, Kirikae T. Complete genome sequence of highly multidrug-resistant Pseudomonas aeruginosa NCGM2.S1, a representative strain of a cluster endemic to Japan. J Bacteriol. 2011;193(24):7010.PubMedPubMedCentralCrossRef Miyoshi-Akiyama T, Kuwahara T, Tada T, Kitao T, Kirikae T. Complete genome sequence of highly multidrug-resistant Pseudomonas aeruginosa NCGM2.S1, a representative strain of a cluster endemic to Japan. J Bacteriol. 2011;193(24):7010.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Shimizu W, Kayama S, Kouda S, Ogura Y, Kobayashi K, Shigemoto N, et al. Persistence and epidemic propagation of a Pseudomonas aeruginosa sequence type 235 clone harboring an IS26 composite transposon carrying the bla IMP-1 integron in Hiroshima, Japan, 2005 to 2012. Antimicrob Agents Chemother. 2015;59(5):2678–87.PubMedPubMedCentralCrossRef Shimizu W, Kayama S, Kouda S, Ogura Y, Kobayashi K, Shigemoto N, et al. Persistence and epidemic propagation of a Pseudomonas aeruginosa sequence type 235 clone harboring an IS26 composite transposon carrying the bla IMP-1 integron in Hiroshima, Japan, 2005 to 2012. Antimicrob Agents Chemother. 2015;59(5):2678–87.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Saito R, Koyano S, Nagai R, Okamura N, Moriya K, Koike K. Evaluation of a chromogenic agar medium for the detection of extended-spectrum ß-lactamase-producing Enterobacteriaceae. Lett Appl Microbiol. 2010;51(6):704–6.PubMedCrossRef Saito R, Koyano S, Nagai R, Okamura N, Moriya K, Koike K. Evaluation of a chromogenic agar medium for the detection of extended-spectrum ß-lactamase-producing Enterobacteriaceae. Lett Appl Microbiol. 2010;51(6):704–6.PubMedCrossRef
13.
Zurück zum Zitat Soria Segarra C, Larrea Vera G, Berrezueta Jara M, Arevalo Mendez M, Cujilema P, Serrano Lino M, et al. Utility of CHROMagar mSuperCARBA for surveillance cultures of carbapenemase-producing Enterobacteriaceae. New Microbes New Infect. 2018;26:42–8.PubMedPubMedCentralCrossRef Soria Segarra C, Larrea Vera G, Berrezueta Jara M, Arevalo Mendez M, Cujilema P, Serrano Lino M, et al. Utility of CHROMagar mSuperCARBA for surveillance cultures of carbapenemase-producing Enterobacteriaceae. New Microbes New Infect. 2018;26:42–8.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fitth informational supplement. M100-S25. Wayne, PA: CLSI; 2015. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-fitth informational supplement. M100-S25. Wayne, PA: CLSI; 2015.
15.
Zurück zum Zitat O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;(47):2437. O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;(47):2437.
16.
Zurück zum Zitat Suzuki M, Hosoba E, Matsui M, Arakawa Y. New PCR-based open reading frame typing method for easy, rapid, and reliable identification of Acinetobacter baumannii international epidemic clones without performing multilocus sequence typing. J Clin Microbiol. 2014;52(8):2925–32.PubMedPubMedCentralCrossRef Suzuki M, Hosoba E, Matsui M, Arakawa Y. New PCR-based open reading frame typing method for easy, rapid, and reliable identification of Acinetobacter baumannii international epidemic clones without performing multilocus sequence typing. J Clin Microbiol. 2014;52(8):2925–32.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol. 2000;66(10):4555–8.PubMedPubMedCentralCrossRef Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol. 2000;66(10):4555–8.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Matsumura Y, Pitout JDD, Peirano G, DeVinney R, Noguchi T, Yamamoto M, et al. Rapid Identification of Different Escherichia coli Sequence Type 131 Clades. Antimicrob Agents Chemother. 2017;61:e00179–17. Matsumura Y, Pitout JDD, Peirano G, DeVinney R, Noguchi T, Yamamoto M, et al. Rapid Identification of Different Escherichia coli Sequence Type 131 Clades. Antimicrob Agents Chemother. 2017;61:e00179–17.
19.
Zurück zum Zitat Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, et al. The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). Nucleic Acids Res. 2014;42(Database issue):D206–14.PubMedCrossRef Overbeek R, Olson R, Pusch GD, Olsen GJ, Davis JJ, Disz T, et al. The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST). Nucleic Acids Res. 2014;42(Database issue):D206–14.PubMedCrossRef
20.
Zurück zum Zitat Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50(4):1355–61.PubMedPubMedCentralCrossRef Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50(4):1355–61.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67(11):2640–4.PubMedPubMedCentralCrossRef Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67(11):2640–4.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST ring image generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402.PubMedPubMedCentralCrossRef Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST ring image generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44(3):827–32.PubMedPubMedCentralCrossRef La Scola B, Gundi VA, Khamis A, Raoult D. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44(3):827–32.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Juan C, Torrens G, Gonzalez-Nicolau M, Oliver A. Diversity and regulation of intrinsic beta-lactamases from non-fermenting and other gram-negative opportunistic pathogens. FEMS Microbiol Rev. 2017;41(6):781–815.CrossRefPubMed Juan C, Torrens G, Gonzalez-Nicolau M, Oliver A. Diversity and regulation of intrinsic beta-lactamases from non-fermenting and other gram-negative opportunistic pathogens. FEMS Microbiol Rev. 2017;41(6):781–815.CrossRefPubMed
26.
Zurück zum Zitat Passarelli-Araujo H, Palmeiro JK, Moharana KC, Pedrosa-Silva F, Dalla-Costa LM, Venancio TM. Genomic analysis unveils important aspects of population structure, virulence, and antimicrobial resistance in Klebsiella aerogenes. FEBS J. 2019;286(19):3797–810.PubMedCrossRef Passarelli-Araujo H, Palmeiro JK, Moharana KC, Pedrosa-Silva F, Dalla-Costa LM, Venancio TM. Genomic analysis unveils important aspects of population structure, virulence, and antimicrobial resistance in Klebsiella aerogenes. FEBS J. 2019;286(19):3797–810.PubMedCrossRef
27.
Zurück zum Zitat Seeberg AH, Tolxdorff-Neutzling RM, Wiedemann B. Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins. Antimicrob Agents Chemother. 1983;23(6):918–25.PubMedPubMedCentralCrossRef Seeberg AH, Tolxdorff-Neutzling RM, Wiedemann B. Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins. Antimicrob Agents Chemother. 1983;23(6):918–25.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Poirel L, Guibert M, Girlich D, Naas T, Nordmann P. Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates. Antimicrob Agents Chemother. 1999;43(4):769–76.PubMedPubMedCentralCrossRef Poirel L, Guibert M, Girlich D, Naas T, Nordmann P. Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates. Antimicrob Agents Chemother. 1999;43(4):769–76.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Ender PT, Gajanana D, Johnston B, Clabots C, Tamarkin FJ, Johnson JR. Transmission of an extended-spectrum-beta-lactamase-producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol. 2009;47(11):3780–2.PubMedPubMedCentralCrossRef Ender PT, Gajanana D, Johnston B, Clabots C, Tamarkin FJ, Johnson JR. Transmission of an extended-spectrum-beta-lactamase-producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol. 2009;47(11):3780–2.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014;111(15):5694–9.PubMedPubMedCentralCrossRef Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014;111(15):5694–9.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–6.PubMedCrossRef Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41(Suppl 2):S120–6.PubMedCrossRef
32.
Zurück zum Zitat Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28(3):565–91.PubMedPubMedCentralCrossRef Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28(3):565–91.PubMedPubMedCentralCrossRef
33.
34.
Zurück zum Zitat Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276–301.PubMedCrossRef Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276–301.PubMedCrossRef
35.
36.
Zurück zum Zitat Nemec A, De Baere T, Tjernberg I, Vaneechoutte M, van der Reijden TJ, Dijkshoorn L. Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens. Int J Syst Evol Microbiol. 2001;51(Pt 5):1891–9.PubMedCrossRef Nemec A, De Baere T, Tjernberg I, Vaneechoutte M, van der Reijden TJ, Dijkshoorn L. Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens. Int J Syst Evol Microbiol. 2001;51(Pt 5):1891–9.PubMedCrossRef
37.
Zurück zum Zitat Mader K, Terhes G, Hajdu E, Urban E, Soki J, Magyar T, et al. Outbreak of septicaemic cases caused by Acinetobacter ursingii in a neonatal intensive care unit. Int J Med Microbiol. 2010;300(5):338–40.PubMedCrossRef Mader K, Terhes G, Hajdu E, Urban E, Soki J, Magyar T, et al. Outbreak of septicaemic cases caused by Acinetobacter ursingii in a neonatal intensive care unit. Int J Med Microbiol. 2010;300(5):338–40.PubMedCrossRef
38.
Zurück zum Zitat Salzer HJ, Rolling T, Schmiedel S, Klupp EM, Lange C, Seifert H. Severe community-acquired bloodstream infection with Acinetobacter ursingii in person who injects drugs. Emerg Infect Dis. 2016;22(1):134–7.PubMedPubMedCentralCrossRef Salzer HJ, Rolling T, Schmiedel S, Klupp EM, Lange C, Seifert H. Severe community-acquired bloodstream infection with Acinetobacter ursingii in person who injects drugs. Emerg Infect Dis. 2016;22(1):134–7.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Endo S, Sasano M, Yano H, Inomata S, Ishibashi N, Aoyagi T, et al. IMP-1-producing carbapenem-resistant Acinetobacter ursingii from Japan. J Antimicrob Chemother. 2012;67(10):2533–4.PubMedCrossRef Endo S, Sasano M, Yano H, Inomata S, Ishibashi N, Aoyagi T, et al. IMP-1-producing carbapenem-resistant Acinetobacter ursingii from Japan. J Antimicrob Chemother. 2012;67(10):2533–4.PubMedCrossRef
40.
Zurück zum Zitat Sieswerda E, Schade RP, Bosch T, de Vries J, Chamuleau MED, Haarman EG, et al. Emergence of carbapenemase-producing Acinetobacter ursingii in the Netherlands. Clin Microbiol Infect. 2017;23(10):779–81.PubMedCrossRef Sieswerda E, Schade RP, Bosch T, de Vries J, Chamuleau MED, Haarman EG, et al. Emergence of carbapenemase-producing Acinetobacter ursingii in the Netherlands. Clin Microbiol Infect. 2017;23(10):779–81.PubMedCrossRef
41.
Zurück zum Zitat Leibovitz A, Dan M, Zinger J, Carmeli Y, Habot B, Segal R. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg Infect Dis. 2003;9(8):956–9.PubMedPubMedCentralCrossRef Leibovitz A, Dan M, Zinger J, Carmeli Y, Habot B, Segal R. Pseudomonas aeruginosa and the oropharyngeal ecosystem of tube-fed patients. Emerg Infect Dis. 2003;9(8):956–9.PubMedPubMedCentralCrossRef
42.
43.
Zurück zum Zitat Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis. 2002;35(3):228–35.PubMedCrossRef Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis. 2002;35(3):228–35.PubMedCrossRef
44.
Zurück zum Zitat Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA. 2004;292(17):2115–24.PubMedCrossRef Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA. 2004;292(17):2115–24.PubMedCrossRef
45.
Zurück zum Zitat Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39(2):219–26.PubMedCrossRef Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39(2):219–26.PubMedCrossRef
46.
Zurück zum Zitat Umezawa K, Asai S, Ohshima T, Iwashita H, Ohashi M, Sasaki M, et al. Outbreak of drug-resistant Acinetobacter baumannii ST219 caused by oral care using tap water from contaminated hand hygiene sinks as a reservoir. Am J Infect Control. 2015;43(11):1249–51.PubMedCrossRef Umezawa K, Asai S, Ohshima T, Iwashita H, Ohashi M, Sasaki M, et al. Outbreak of drug-resistant Acinetobacter baumannii ST219 caused by oral care using tap water from contaminated hand hygiene sinks as a reservoir. Am J Infect Control. 2015;43(11):1249–51.PubMedCrossRef
47.
Zurück zum Zitat Liu C, Cao Y, Lin J, Ng L, Needleman I, Walsh T, et al. Oral care measures for preventing nursing home-acquired pneumonia. Cochrane Database Syst Rev. 2018;9:CD012416.PubMed Liu C, Cao Y, Lin J, Ng L, Needleman I, Walsh T, et al. Oral care measures for preventing nursing home-acquired pneumonia. Cochrane Database Syst Rev. 2018;9:CD012416.PubMed
48.
Zurück zum Zitat Hollaar VRY, van der Putten GJ, van der Maarel-Wierink CD, Bronkhorst EM, de Swart BJM, de Baat C, et al. Nursing home-acquired pneumonia, dysphagia and associated diseases in nursing home residents: a retrospective, cross-sectional study. Geriatr Nurs. 2017;38(5):437–41.PubMedCrossRef Hollaar VRY, van der Putten GJ, van der Maarel-Wierink CD, Bronkhorst EM, de Swart BJM, de Baat C, et al. Nursing home-acquired pneumonia, dysphagia and associated diseases in nursing home residents: a retrospective, cross-sectional study. Geriatr Nurs. 2017;38(5):437–41.PubMedCrossRef
49.
Zurück zum Zitat Low LF, Fletcher J, Goodenough B, Jeon YH, Etherton-Beer C, MacAndrew M, et al. A systematic review of interventions to change staff care practices in order to improve resident outcomes in nursing homes. PLoS One. 2015;10(11):e0140711.PubMedPubMedCentralCrossRef Low LF, Fletcher J, Goodenough B, Jeon YH, Etherton-Beer C, MacAndrew M, et al. A systematic review of interventions to change staff care practices in order to improve resident outcomes in nursing homes. PLoS One. 2015;10(11):e0140711.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Quagliarello V, Ginter S, Han L, Van Ness P, Allore H, Tinetti M. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis. 2005;40(1):1–6.PubMedCrossRef Quagliarello V, Ginter S, Han L, Van Ness P, Allore H, Tinetti M. Modifiable risk factors for nursing home-acquired pneumonia. Clin Infect Dis. 2005;40(1):1–6.PubMedCrossRef
51.
Zurück zum Zitat Schwendicke F, Stolpe M, Muller F. Professional oral health care for preventing nursing home-acquired pneumonia: a cost-effectiveness and value of information analysis. J Clin Periodontol. 2017;44(12):1236–44.PubMedCrossRef Schwendicke F, Stolpe M, Muller F. Professional oral health care for preventing nursing home-acquired pneumonia: a cost-effectiveness and value of information analysis. J Clin Periodontol. 2017;44(12):1236–44.PubMedCrossRef
Metadaten
Titel
Oral colonisation by antimicrobial-resistant Gram-negative bacteria among long-term care facility residents: prevalence, risk factors, and molecular epidemiology
verfasst von
Mi Nguyen-Tra Le
Shizuo Kayama
Mineka Yoshikawa
Toshinori Hara
Seiya Kashiyama
Junzo Hisatsune
Keiko Tsuruda
Makoto Onodera
Hiroki Ohge
Kazuhiro Tsuga
Motoyuki Sugai
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Antimicrobial Resistance & Infection Control / Ausgabe 1/2020
Elektronische ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-020-0705-1

Weitere Artikel der Ausgabe 1/2020

Antimicrobial Resistance & Infection Control 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.